This practical referene for drug developers addresses the most common antitarget–related side effects, including hepatic, cardiovascular, kinase– and GPCR–mediated toxicity. Current strategies how to manage side effects as well as several case studies are included. INDICE: SECTION 1: GENERAL CONCEPT FOR TARGET–BASED SAFETY ASSESSMENT.Analysis of marketed drugs: The utility of AERS for early drugdiscovery .How to interpret anti–target data: Introduction of the concept ofcoverage .In silico applications to find unknown side effects .Translational value of preclinical safety assessment: how toconsider targets in SOCs .Pathological conditions associated with the disturbance of 5HTreceptors ..SECTION 2: HEPATIC SIDE EFFECTS .DILI: Mechanisms & Detection.Hepatotox assays .Transporters in the liver..SECTION 3: CARDIOVASCULAR SIDE EFFECTS .Chronotropic effects, ionotropic effects, general hemodynamiceffects .Cav1.2 .Nav 1.5.Circulating biomarkers for cardiotoxicity: reverse translation fromhuman to preclinical species.hERG..SECTION 4: INASE ANTITARGETS.Introduction to Kinase Anti–Targets.Kinase Targets with CV safety issues .Kinase Signalling and AEs –.Preclinical connection.Kinase Signalling and AEs –.Clinical Connection.Case Study I.Case Study II..SECTION 5: EXAMPLES .Labels & blackbox warnings.Rimonabant.Torcetrapib/Dalcetrapib.Pharmacology of suicidal intent.
- ISBN: 978-3-527-33511-4
- Editorial: Wiley VCH
- Encuadernacion: Cartoné
- Páginas: 520
- Fecha Publicación: 22/04/2015
- Nº Volúmenes: 1
- Idioma: Inglés